High density associated enzymes: Their role in Vascular biology

Current Opinion in Lipidology

Volumn 9, Issue 5, 1998, Pages 449-456

  Navab, Mohamad ^a   Hama, Susan Y ^a   Hough, Greg P ^a   Hedrick, Catherine C ^a   Sorenson, Robert ^a   La Du, Burt N ^b   Kobashigawa, Jon A ^a   Fonarow, Gregg C ^a   Berliner, Judith A ^a   Laks, Hillel ^a   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARYLESTERASE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; ENZYME; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID TRANSFER PROTEIN;

ARTERY WALL; BLOOD VESSEL; METABOLISM; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARTERIES; ARYLDIALKYLPHOSPHATASE; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; ENZYMES; ESTERASES; GLYCOPROTEINS; LIPOPROTEINS, HDL; MEMBRANE PROTEINS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PHOSPHOLIPASES A; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 14444268970     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199810000-00009     Document Type: Review

References (69)

1. Thornburg JT, Parks JS, Rudel LL. Dietary fatty acid modification of HDL phospholipid molecular species alters lecithin: cholesterol acyltransferase reactivity in cynomolgus monkeys. J Lip Res 1995; 36:277-289.
2. Liu M, Bagdade JD, Subbaiah PV. Specificity of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. J Lip Res 1995; 36:1813-1824.
3. Subbaiah PV, Liu M. Comparative studies on the substrate specificity of LCAT towards the molecular species of phosphatidylcholine in the plasma of 14 vertebrates. J Lip Res 1996; 37:113-122.
4. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein Al and human apolipoprotein All on plasma lipoprotein cholesterol metabolism. J Clin Invest 1995; 96:1440-1448.
5. Vaisman BL, Klein HG, Rouis M, Berard AM, Kindt MR, Talley GD, et al. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 1995; 270:12269-12275.
6. Hoeg JM, Vaisman BL, Demosky SJ Jr, Meyn SM, Talley GD, Hoyt RF Jr, et al. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 1996; 271:4396-4402.
7. Francone OL, Evangelista L, Fielding CJ. Effects of carboxy-terminal truncation on human lecithin:cholesterol acyltransferase activity. J Lip Res 1996; 37:1609-1615.
8. Wang J, Gebre AK, Anderson RA, Parks JS. Amino acid residue 149 of lecithin:cholesterol acyltransferase determines phospholipase A2 and transacylase fatty acyl specificity. J Biol Chem 1997; 272:280-286.
9. Sparks DL, Anantharamaiah GM, Segrest JP, Phillips MC. Effect of the cholesterol content of reconstituted LpA-I on lecithin:cholesterol acyltransferase activity. J Biol Chem 1995; 270:5151-5157.
10. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW, Landrum M. The hydrophobic face orientation of apolipoprotein A-I amphipathic helix domain 143-164 regulates lecithin:cholesterol acyltransferase activation. J Biol Chem 1998; 273:11776-11782.
11. Sorci-Thomas MG, Curtiss L, Parks JS, Thomas MJ, Kearns MW. Alteration in apolipoprotein A-I 22-mer repeat order results in a decrease in lecithin:cholesterol acyltransferase reactivity. J Biol Chem 1997; 272:7278-7284.
12. Lindholm EM, Bielicki JK, Curtiss LK, Rubin EM, Forte TM. Deletion of amino acids Glu146 → Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid. Biochemistry 1998; 37:4863-4868.
13. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high-density lipoproteins containing ApoA-II in classic lecithin: cholesterol-acyltransferase deficiency and fish-eye disease. J Clin Invest 1994; 93:321-330.
14. Steyrer E, Durovic S, Frank S, Giessauf W, Burger A, Dieplinger H, et al. The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994; 94:2330-2340.
15. Liu M, Bagdade JD, Subbaiah PV. Specificity of lecithin: cholesterol acyltransterase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. J Lip Res 1995; 36:1813-1824.
16. Bielicki JK, Forte TM, McCall MR. Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity. J Lip Res 1996; 37:1012-1021.
17. Tall A. Plasma lipid transfer proteins. Ann Rev Biochem 1995; 64:235-257.
18. Dullaart RP, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994; 24:188-194.
19. Dullaart RP, Hoogenberg K. Dikkeschei BD, van Tol A. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 1994; 14:1581-1585.
20. Kostner GM, Oettl K, Jauhiainen M, Ehnholm C, Esterbauer H, Dieplinger H. Human plasma phospholipid transfer protein accelerates exchange/transfer of alpha-tocopherol between lipoproteins and cells. Biochem J 1995; 305:659-667.
21. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J 1996; 313:275-282.
22. Hailman E, Albers JJ, Wolfbauer G, Tu AY, Wright SD. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem 1996; 271:12172-12178.
23. von Eckardstein A, Jauhiainen M, Huang Y, Metso J, Langer C, Pussinen PS, et al. Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL. Biochim Biophys Acta 1996; 1301:255-262.
24. Cheung MC, Wolfbauer G, Albers JJ. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim Biophys Acta 1996; 1303:103-110.
25. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, et al. Increased prebeta-high density lipoprotein, apolipoprotein Al, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein Al transgenes. J Clin Invest 1996; 98:2373-2380.
26. Rao R, Albers JJ, Wolfbauer G, Pownall HJ. Molecular and macromolecular specificity of human plasma phospholipid transfer protein. Biochemistry 1997; 36(12):3645-53.
27. Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer HB Jr. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem 1997; 272:27393-273400.
28. Lagrost L, Athias A, Herbeth B, Guyard-Dangremont V, Artur Y, Paille F, et al. Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem 1996; 271:19058-19065.
29. Desrumaux C, Athias A, Masson D, Gambert P, Lallemant C, Lagrost L. Influence of the electrostatic charge of lipoprotein particles on the activity of the human plasma phospholipid transfer protein. J Lip Res 1998; 39:131-142.
30. Pussinen PJ, Jauhiainen M, Metso J, Pyle LE, Marcel YL, Fidge NH, Ehnholm C. Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I. J Lip Res 1998; 39:152-161.
31. Pussinen PJ, Jauhiainen M, Ehnholm C. ApoA-II/apoA-I molar ratio in the HDL particle influences phospholipid transfer protein-mediated HDL interconversion. J Lip Res 1997; 38:12-21.
32. Huuskonen J, Olkkonen VM, Jauhiainen M, Sareneva T, Somerharju P, Ehnholm C. Oxidative modification of HDL3 in vitro and its effect on PLTP-mediated phospholipid transfer. Biochim Biophys Acta 1998; 1391:181-192.
33. Van Tol A, Ligtenberg JJ, Riemens SC, van Haeften TW, Reitsma WD, Dullaart RP. Lowering of plasma phospholipid transfer protein activity by acute hyperglycaemia-induced hyperinsulinaemia in healthy men. Scand J Clin Lab Invest 1997; 57:147-157.
34. Rye KA, Jauhiainen M, Barter PJ, Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodeling by phospholipid transfer protein. J Lip Res 1998; 39:613-622.
35. La Du BN. Human serum paraoxonase/arylesterase. In Pharmacogenetics of drug metabolism. W. Kalow, editor, New York. Pergamon Press, Inc. 1992, pp. 51-91.
36. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7:69-76.
37. Watson AD, Berliner JA, Hama SY, La Du B, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-2891.
38. Blatter Garin MC, Abbott C, Messmer S, Mackness M, Durrington P, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994; 304:549-554.
39. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96:3005-3008.
40. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57:69-73.
41. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler, Thromb Vasc Biol 1995; 15:89-95.
42. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346:869-872.
43. Heinecke JW, Lusis AJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Human Genet 1998; 62:20-24.
44. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98:883-685.
45. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15:1812-1818.
46. Sorenson RC, Primo-Parmo SL, Camper SA, La Du BN. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics 1995; 30:431-438.
47. Li WF, Matthews C, Disteche CM, Costa LG, Furlong CE. Paraoxonase gene in mice: sequencing, chromosomal localization and developmental expression. Pharmacogenetics 1997; 7:137-144.
48. Shin DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
49. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996; 16:1243.
50. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99:62-66.
51. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997; 17:2935-2939.
52. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio J Clin Invest 1997; 99:2005-2019.
53. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236:289-293.
54. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler ThrombVasc Biol 1997; 17:1233-1238.
55. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. Febs Letters 1997; 416:377-380.
56. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590.
57. Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998; 26:355-359.
58. Shih DM, Gu LJ, Xia YR, Navab M, Li W-F, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287.
59. Ho YS, Swenson L, Derewenda U, Serre L, Wei Y, Dauter Z, et al. Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer. Nature 1997; 385:89-93.
60. Cao Y, Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 1998; 273:4012-4020.
61. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lip Res 1997; 38:2281-2288.
62. Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997; 27:595-602.
63. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97:2784-2791.
64. Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 1995; 270:31151-31157.
65. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimp B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase [see comments]. Nature 1995; 374:549-553.
66. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipidsas substrates. J Biol Chem 1991; 266:11095-11103.
67. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95:774-782.
68. Ambrosio G, Oriente A, Napoli C, Palumbo G, Chiariello P, Marone G, et al. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest 1994; 93:2408-2416.
69. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16:831-842.